What is BEAM's P/E ratio?

Beam Therapeutics Inc (BEAM) currently trades at a P/E ratio of 10.75.

Beam Therapeutics Inc reports a Return on Equity (ROE) of -5.59%.

What is BEAM's dividend yield?

Beam Therapeutics Inc offers a dividend yield of 0.00%.

What is BEAM's Quality Score?

Our AI rates BEAM's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy BEAM?

Our AI Timing Score for BEAM is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does BEAM belong to?

Beam Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Beam Therapeutics Inc (BEAM) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

BEAM AI Analysis Summary

Our AI summary for BEAM: Beam Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 10.75, ROE of -5.59%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

BEAM

Beam Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 25.91

0.39 (1.53%) Day Change

Watchlist Portfolio Compare Chart

10.75

P/E

0.10

D/E

-5.6%

ROE

-4.4%

ROA

0.00%

Div Yield

BEAM THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 25.91 Price 0.39 (1.53%) Day Change	NEWS SCORE: N/A

BEAM, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.12 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	25.91
PBV / Sector	2.25 / 44,219.29
Earning Per Share	-0.64

PE / Sector	10.75 / 19.28 GOOD
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	68.33 M
Average 1W Daily Value	39.74 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-39.66 / 98.22
NPM Average (%) / Sector	-239.93 / -1,697.63
NPM Change Average (%) / Sector	344.19 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-4.39 / 185,260.96
ROA Average (%) / Sector	-14.91 / 36,684.70
ROA Change Average (%) / Sector	28.81 / 422,221.66 GREAT
ROE (%) / Sector	-5.59 / 243,762.23
ROE Average (%) / Sector	-23.26 / 48,758.47
ROE Change Average (%) / Sector	28.40 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:12
Symbol	BEAM
Name	BEAM THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	102.88 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,625.48 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 238 Main Street, Cambridge, MA, United States, 02142

Phone: 857 327 8775

Website: https://beamtx.com

Employees: 522

Sector: Healthcare >> Biotechnology

Description: Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.